Immunologic Research

, Volume 29, Issue 1–3, pp 197–208 | Cite as

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer

  • Robert S. Mittler
  • Juergen Foell
  • Megan McCausland
  • Simona Strahotin
  • Liguo Niu
  • Abhijit Bapat
  • L. Becker Hewes
Immunology at Emory University

Abstract

CD137 (4-1BB), is an inducible T-cell costimulatory receptor and a member of the tumor necrosis factor receptor (TNFR) superfamily. It is expressed on activated T cells and activated natural killer (NK) cells, but is constitutively expressed on a population of splenic dendritic cells, (DCs). The natural counter receptor for CD137 is 4-1BB ligand, a member of the TNf superfamily that is weakly expressed on naïve or resting B cells, macrophages, and DCs. Upon activation, the level of 4-1BBL expression increases on these cells. In T cells CD137-induced signals lead to the recruitment of TRAF family members and activation of several kinases, including ASK-1, MKK, MAPK3/MAPK4, p38, and JNK/SAPK. Kinase activation is then followed by the activation and nuclear translocation of several transcription factors, including ATF-2, Jun, and NF-κB. CD137-mediated T-cell costimulation as measured by enhanced proliferation and cytokine production can be induced by anti-CD137 monoclonal antibodies (MAbs) or by employing immobilized 4-1BB ligand. In addition to augmenting suboptimal TCR-induced proliferation, CD137-mediated signaling protects T cells, and in particular, CD8+T cells from activation-induced cell death (AICD). Although studies with CD137-deficient or 4-1BBL-deficient mice failed to demonstrate any loss of essential immunological function, or other noteworthy deficits, we have found that 4-1BBL-deficient mice failed to generate a strong antiviral immune response following lymphocytic choriomeningitis virus (LCMV) peptide vaccination. We further found that although compromised, the immune response to LCMV vaccination in these mice could be fully restored by injecting them with anti-CD137 MAbs at the time of vaccination. Finally, we have found that injecting normal mice with anti-CD137 MAbs had profound effects on their ability to develop immune responses to allo- and autoantigens. The results of these studies discussed in this article provide a rationale for assessing the potential use of anti-CD137 MAbs for therapeutic purposes.

Key Words

T-cells Costimulation Tumor immunity Autoimmunity Systemic lupus erythematosus (SLE) Rheumatoid arthritis (RA) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 1970;169:1042–1049.PubMedCrossRefGoogle Scholar
  2. 2.
    Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065–1068.PubMedCrossRefGoogle Scholar
  3. 3.
    Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P: Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 1985;135:2331–2336PubMedGoogle Scholar
  4. 4.
    Lane P: A molecular basis for T-dependent B cell activation. Behring Inst Mitt 1995;96:7–12.PubMedGoogle Scholar
  5. 5.
    Baker SJ, Reddy EP: Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261–3270.PubMedCrossRefGoogle Scholar
  6. 6.
    Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993;150:771–781.PubMedGoogle Scholar
  7. 7.
    DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade WF, Kwon BS, Watts TH: Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995;181:985–992.PubMedCrossRefGoogle Scholar
  8. 8.
    Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8T cell survival signal. J Immunol 1999;162:5037–5040.PubMedGoogle Scholar
  9. 9.
    Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A: 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 2002;14:1155–1167.PubMedCrossRefGoogle Scholar
  10. 10.
    Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK: Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999;190:1535–1540.PubMedCrossRefGoogle Scholar
  11. 11.
    Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al.: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682–685.PubMedCrossRefGoogle Scholar
  13. 13.
    Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, et al.: CD137 costimulatory T cell receptor engagement reverses acute disease in lupusprone NZB×NZW F1 mice. J Clin Invest 2003;111:1505–1518.PubMedCrossRefGoogle Scholar
  14. 14.
    Tan JT, Whitmire JK, Murali-Krishna K, Ahmed R Altman JD, Mittler RS, et al.: 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000;164:2320–2325.PubMedGoogle Scholar
  15. 15.
    Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, et al.: Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262–4267.PubMedGoogle Scholar
  16. 16.
    Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K: Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002;14:275–286.PubMedCrossRefGoogle Scholar
  17. 17.
    Langstein J, Michel J, Schwarz H: CD137 induces proliferation and endomitosis in monocytes. Blood 1999;94:3161–3168.PubMedGoogle Scholar
  18. 18.
    Langstein J, Schwarz H: Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 1999;65:829–833.PubMedGoogle Scholar
  19. 19.
    Boussaud V, Soler P, Moreau J, Goodwin RG, Hance AJ: Expression of three members of the TNF-R family of receptors (4-1BB, lymphotoxin-beta receptor, and Fas) in human lung. Eur Respir J 1998;12:926–931.PubMedCrossRefGoogle Scholar
  20. 20.
    Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H: CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 2001;115:543–549.PubMedCrossRefGoogle Scholar
  21. 21.
    Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH: 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313–1324.PubMedGoogle Scholar
  22. 22.
    Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001;15:397–408.PubMedCrossRefGoogle Scholar
  23. 23.
    Wofsy D, Seaman WE: Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985;161:378–391.PubMedCrossRefGoogle Scholar
  24. 24.
    Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G: Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166:4312–4318.PubMedGoogle Scholar
  25. 25.
    Kim YJ, Pollok KE, Zhou Z, Shaw A, Bohlen JB, Fraser M, Kwon BS: Novel T cell antigen 4-1BB associates with the protein tyrosine kinase p56lck1. J Immunol 1993;151:1255–1262.PubMedGoogle Scholar
  26. 26.
    Arch RH, Thompson CB: 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998;18:558–565.PubMedGoogle Scholar
  27. 27.
    Saoulli K, Lee SY, Cannons JL, Yeh WC, Santana A, Goldstein MD, et al.: CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998;187:1849–1862.PubMedCrossRefGoogle Scholar
  28. 28.
    Cannons JL, Choi Y, Watts TH: Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol 2000;165:6193–6204.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  • Robert S. Mittler
    • 1
    • 2
  • Juergen Foell
    • 1
    • 2
  • Megan McCausland
    • 1
    • 2
  • Simona Strahotin
    • 1
    • 2
  • Liguo Niu
    • 1
    • 2
  • Abhijit Bapat
    • 4
  • L. Becker Hewes
    • 2
    • 3
  1. 1.Department of SurgeryEmory University School of MedicineAtlanta
  2. 2.Emory Vaccine Research CenterEmory University School of MedicineAtlanta
  3. 3.Department of Pediatric Hematology and OncologyEmory University School of MedicineAtlanta
  4. 4.Albert Einstein School of MedicineNew York

Personalised recommendations